Meta-Analysis: Pharmacologic Treatment of Obesity

View larger version (37K): [in a new window]   Figure 1. Literature flow. HTA = Health Technology Assessment; NHS = National Health Service. *See the companion article by Maggard et al. in this issue. These 39 articles were randomized, controlled trials and reviews of sibutramine, phentermine, and diethylpropion.

View larger version (15K): [in a new window]   Figure 2. Pooled analysis of weighted mean difference in weight loss with sibutramine versus placebo at 44 to 54 weeks. Data are from reference 35. P = 0.14 (chi-square test); I2 = 43%.

View larger version (42K): [in a new window]   Figure 3. Pooled analysis of mean difference in weight loss with orlistat versus placebo at 12 months.P = 0.00 (chi-square test); I2 = 83%.

View larger version (21K): [in a new window]   Figure 4. Pooled analysis of weight loss with bupropion and fluoxetine versus placebo at 6 to 12 months. For bupropion, P = 0.00 (chi-square test) and I2 = 84%. For fluoxetine, P = 0.00 (chi-square test) and I2 = 85%.

View larger version (18K): [in a new window]   Figure 5. Pooled analysis of weight loss with topiramate versus placebo at 6 months.P = 0.00 (chi-square test) and I2 = 87%.

View this table: [in a new window]   Appendix Table. Evidence Table of Randomized, Controlled Trials